Digital Mental Health Technologies Shape New Regulatory Landscape

Over 1 billion people globally are currently living with mental health conditions, according to the World Health Organization (WHO). Mental health issues, particularly depression and anxiety, are costing the global economy approximately US$ 1 trillion annually. In the UK, a recent survey revealed that 1 in 6 individuals reported being diagnosed with depression, while 1 in 7 experienced anxiety. Additionally, 10% of respondents reported moderate to severe depressive symptoms in the last two weeks. These statistics underscore an urgent need for effective mental health support, as traditional services struggle to meet rising demand.

The surge in interest for scalable and accessible alternatives has led to the rapid development of Digital Mental Health Technologies (DMHTs). These range from smartphone applications and online platforms to AI-driven tools, which are increasingly viewed as essential for bridging the treatment gap. The global market for mental health devices and platforms was valued at $3.22 billion in 2023 and is projected to reach $17.70 billion by 2031.

Regulatory Changes for Digital Mental Health Tools

As DMHTs gain traction, regulatory frameworks are evolving to address the unique challenges they present. In February 2025, the Medicine and Healthcare products Regulatory Agency (MHRA) in the UK released guidance aimed at clarifying when DMHTs qualify as medical devices. The new document, titled “Digital mental health technology: qualification and classification,” was developed as part of a broader project backed by the UK government, involving a £1.8 million investment.

This guidance establishes clear criteria for categorizing these digital tools, primarily based on two factors: the intended medical purpose and the complexity of functionality. If a DMHT is designed for a medical purpose and incorporates sophisticated features, it is classified as Software as a Medical Device (SaMD). Consequently, manufacturers must comply with stringent safety, performance, and clinical evidence standards. Conversely, simpler tools, such as basic wellbeing applications, may qualify for lower-risk classifications and can self-certify as Class I medical devices.

The implications of the MHRA’s new guidance extend beyond new technologies; it also affects existing products. Many DMHTs have expanded their functionalities since their initial launches, incorporating advanced AI features that alter their regulatory status. For instance, a mental health app originally deemed a wellbeing tool may now require reclassification if it introduces capabilities like AI-based mood analysis or clinical decision support. This evolving landscape necessitates vigilance among developers to avoid “functional drift,” where incremental feature changes inadvertently shift a product into a higher risk category.

Global Regulatory Approaches and Challenges

The MHRA’s guidance is part of a broader initiative aimed at modernizing the regulation of software and AI as medical devices, known as the Software and AI as a Medical Device Change Programme, launched in October 2022. This programme recognizes the specific challenges associated with AI-driven medical devices, such as algorithm updates, continuous learning risks, and the need for comprehensive post-market surveillance.

In the United States, the Food and Drug Administration (FDA) has also published guidance, including the Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. Unlike the MHRA’s more standardized approach, the FDA evaluates technologies on a case-by-case basis, considering their risk classification and intended use. Similarly, the European Union is set to enforce the EU AI Act, effective from August 1, 2024, establishing a rigorous regulatory framework for AI in healthcare, categorizing many AI systems as high-risk and imposing extensive requirements for risk management and technical documentation.

Despite the promising developments in DMHT regulation, reimbursement remains a significant hurdle. Many digital health tools lack established national reimbursement routes, with adoption often reliant on pilot programs and local commissioning decisions. Successful DMHTs are typically those that demonstrate clear value to health systems, such as reducing clinician workload or improving patient outcomes.

For innovators in the DMHT space, the emphasis is on defining purpose, ensuring safety from the outset, and generating robust evidence to support their products. As digital mental health technologies evolve, the potential for improved access to mental health support is significant, but achieving this will require responsible development and transparent regulation.

As DMHTs transition from experimental stages to widespread use, their success will hinge on regulatory clarity, clinical credibility, and demonstrated value for healthcare providers. Developers who view regulation as a strategic facilitator rather than a compliance obstacle will be better positioned to scale their solutions effectively, ultimately benefiting patients and health systems alike.

With the rise of AI and enhanced digital tools, ongoing oversight and adaptive regulatory frameworks will be essential in ensuring that innovation leads to meaningful and lasting improvements in mental health support.